<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185159</url>
  </required_header>
  <id_info>
    <org_study_id>SE-866/44</org_study_id>
    <nct_id>NCT00185159</nct_id>
  </id_info>
  <brief_title>Olmesartan Medoxomil in Diabetes Mellitus</brief_title>
  <official_title>Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sankyo Pharma Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      This is a study in diabetic patients with at least one additional cardiovascular risk factor
      and normoalbuminuria prior to randomization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine</measure>
    <time_frame>Time to the first occurrence</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular mortality and morbidity</measure>
    <time_frame>Time to occurence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of renal disease, such as worsening of renal function as well as end-stage (dialysis)</measure>
    <time_frame>Time to occurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and progression of retinopathy</measure>
    <time_frame>Time to occurence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment effects on a combined endpoint of cardiovascular mortality and morbidity and renal disease</measure>
    <time_frame>Time to occurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Throughout entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4449</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>tablets</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Tablets</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus type 2, defined as fasting blood glucose of greater than or equal to
             126 mg/dL;

          -  Presence of at least one of the following cardiovascular risk factors:

               1. total cholesterol greater than 200 mg/dL or statin treatment,

               2. High density lipoprotein (HDL) less than 40 mg/dL,

               3. triglycerides greater than 150 mg/dL and less than 400 mg/dL,

               4. blood pressure greater than or equal to 130/80 mmHg,

               5. Body mass index (BMI) greater than 28 kg/m2,

               6. waist circumference greater than 102 cm for men and greater than 88 cm for women,

               7. smoking of more than 5 cigarettes a day;

          -  Normoalbuminuria at screening

        Exclusion Criteria:

          -  Severe uncontrolled hyperlipidemia;

          -  Documented renal and/or renal-vascular disease;

          -  Myocardial infarction, stroke or myocardial revascularization within the last 6
             months;

          -  History of alcohol and/or drug abuse;

          -  Allergic reaction, lack of response or contraindication to angiotensin receptor
             blockers (ARBs);

          -  Current treatment with an ARB or angiotensin converting enzyme (ACE) inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Hermann Haller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Hochschule Hannover Klinik fur Nieren, Hannover Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Heiko Rauer</name_title>
    <organization>Daiichi Sankyo Europe, GmbH</organization>
  </responsible_party>
  <keyword>Microalbuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

